Monday, June 6, 2016

BRIEF-Merrimack Pharmaceuticals posts results from refractory solid tumor study

* Announced results from final analysis of phase 1 study of

mm-151 in patients with refractory solid tumors

Read more
Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)